RARE News

Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Ultragenyx Pharmaceutical Inc. to Contact the Firm Today!

Pomerantz LLP Notifies Investors of Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. – RARE

RARE DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Ultragenyx Lawsuit - RARE

ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ: RARE) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by April 6, 2026

Class Action Lawsuit Reminder from Pomerantz LLP for Shareholders of Ultragenyx Pharmaceutical Inc. – RARE

RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Ultragenyx Pharmaceutical Inc. to Contact the Firm Today!

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline